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INTRODUCTION
Ovarian cancer is the commonest cause of death from gynaecological malignancy in
the Western world. About 5000 new cases of this cancer are diagnosed each year in
England and Wales (5% of all cancers), and it is the fourth commonest cancer in all
women up to 85 years (after cancers of the breast, lung and large bowel).1 The life-time
risk of developing ovarian cancer, in England and Wales, is 1 in 56, or 1.8% by the age
of 85.2 Ovarian cancer incidence in England and Wales has increased gradually in the
last two decades.1,3 Mortality rates are only slightly lower than the incidence rates1,3
– a reflection of its poor prognosis. In England and Wales, only 29% of women with
the malignancy survive as long as five years after diagnosis although younger women
do survive longer : 69% of those who are under 40 years old at diagnosis survive for
five years compared to less than 20% for those aged 70 or more.4 Because of its high
incidence and poor prognosis, ovarian cancer also represents the fourth most common
cause of death from cancer among women in England and Wales, accounting for about
3600 deaths per year (7% of all cancer deaths).1
The incidence of ovarian cancer shows marked geographical variation. The age-
adjusted annual incidence for England and Wales is about 18 per 100,000 women,1
compared with 24 per 100,000 in Sweden, 8 per 100,000 in Spain and even lower figures
in Japan, South America and India.5,6 It seems unlikely, however, that this variation
between countries can be explained solely by genetic differences, as migrants from
low- to high-risk areas shift their risk to that of the host country. For instance, women
of Chinese and Japanese origin who live in the USA tend to have higher rates than
their Asian counterparts, although the disease is still less common in them than in
the US white population.7
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The large majority of ovarian cancers are epithelial in origin (about 90%), while
germ cell tumours account for less than 5%, and stromal cell tumours for an even
smaller percentage. Unlike ovarian germ cell tumours, epithelial ovarian carcinoma
is extremely uncommon at young ages, with 90% of cases occurring after the age of
45 years. This review will concentrate on epithelial ovarian carcinoma only.
RISK FACTORS FOR EPITHELIAL OVARIAN CANCER
Epidemiological research has consistently shown that high parity, late age at first
birth, use of combined oral contraceptives, tubal ligation and hysterectomy (with
conservation of the ovaries) are associated with a reduction in the risk of ovarian
cancer, whereas a family history of breast and ovarian cancers is associated with an
increase in risk. Dietary factors (e.g. intake and/or metabolism of galactose8), exposure
to ionizing radiation9 and to certain chemical carcinogens (e.g. tale10) have also been
found to be associated with an excess risk in some studies, but not in others. There
is also some evidence that infertility and ovulation-induction drugs may increase the
risk of ovarian cancer and this will be discussed in detail later in this paper.
Pregnancy exerts a strong protective effect against ovarian cancer. Cramer et al.11
showed that women with one or two children have half the risk, those with three
or four children have one-third the risk, and those with five or more children, one-
quarter the risk of ovarian cancer in nulliparous women. Kvale et al.12 estimated
that the risk in women with five or more children was only 0.46 (95% confidence
interval (CI) = 0.30–0.72) of that in women with just one child after adjustment
for age, place of residence (urban/rural) and occupational class. This study also
suggested that uncompleted pregnancies (abortions) were protective. In a case–control
study nested within a large Swedish cohort,13 increasing parity was found to be
associated with a progressive decrease in ovarian cancer risk, a protective effect that
persisted for decades. It is unlikely that the increased risk of ovarian cancer among
nulliparous women could reflect an independent association between ovarian cancer
and infertility. First, the risk declined progressively with each additional birth, even
among women who already had several children. Thus it is improbable that there
is an appreciable frequency of some condition (e.g. endometriosis or a hormonal
abnormality) that can cause both infertility and ovarian cancer in these women.
Second, some studies (e.g. Booth et al.14) found that there remained a steadily declining
risk of ovarian cancer with increasing number of pregnancies even after adjusting for
the number of contraceptive-free years of sexual activity.
The relationship between age at first birth and ovarian cancer is less clear, but there
is now evidence for an effect of decreasing risk with increasing age at first birth.13,15
A 10% decrease in the risk of epithelial ovarian cancer for each five-year increment in
age at first childbirth was observed in the large Swedish cohort described above, this
effect being independent of that of parity.13
Oral contraceptives “mimic pregnancy” by suppressing ovulation and reducing
the secretion of pituitary gonadotrophins. As a result, one would expect oral
Does ovarian stimulation increase the risk of ovarian cancer? 59
contraceptives to reduce the risk of ovarian cancer. This relationship has now been
assessed in a large number of case–control and cohort studies. Risk in ever-users is,
on average, about 50% of that in never-users, with the degree of protection increasing
with duration of use.15−17 The protective effect of oral contraceptive use seems
to persist for 15 years or more.15−17 In some studies (e.g. Franceschi et al.17), the
protective effect was more marked for women who reported their first use before
25 years of age but this finding has not been confirmed by others.15,16 However,
the separate effects of age at first use, time since first and last use, and duration of
use are not easy to disentangle. There is also evidence that oral contraceptives may
reduce the risk of ovarian cancer in carriers of mutations of the BRCA1 or BRCA2
genes, the protective effect increasing with duration of use.18 More recent studies
have shown that modern low-dose pills are also associated with reductions in risk.19
Many studies have suggested that tubal ligation or hysterectomy (with ovarian
conservation) reduce the risk of subsequent ovarian cancer.15,20−22 These observations
may be a result of bias, in that early ovarian disease may be detected during surgery and
the diseased ovary removed. However, not all surgery allows a view of the ovaries, and
another explanation may be that surgery in some way impairs ovarian blood supply
and, hence, reduces ovulation.15,22,23
Early hypotheses about the aetiology of epithelial ovarian cancer implicated
ovulation and gonadotrophins. Fathalla postulated that “incessant ovulation” led to
frequent disruption of the ovarian surface epithelium, with subsequent neoplasia.24,25
His arguments were supported by the observation that the domestic hen, which was
bred for egg-laying, developed ovarian cancer. Cruickshank26 added support to the
ovulation theory by showing that ovarian cancer was more likely to occur on the
right side – in women ovulation occurs significantly more often on the right.26,27
However, while a single pregnancy and subsequent lactation reduced the total number
of ovulations by only 3%, the impact of a single pregnancy was to reduce the risk of
ovarian cancer by half.28
The gonadotrophin theory appears to originate from a letter by Stadl in the
American Journal of Obstetrics and Gynecology,29 pondering why the incidence of
epithelial ovarian cancer remained high after the menopause, proposing that this
was due to rising pituitary gonadotrophin levels, and suggesting that menopausal
estrogen therapy would decrease the risk. But subsequent studies did not find higher
gonadotrophin levels in women who went on to develop ovarian cancer compared to
those who did not.30
The observed decline in the risk of ovarian cancer with increasing parity, oral
contraceptive use and lactation, all of which suppress ovulation, fits with the incessant
ovulation hypothesis (although this hypothesis cannot account for the magnitude of
the decline in risk associated with pregnancy). Perhaps surprisingly, published data
on early menarche and late menopause do not show a consistent pattern of increasing
risk,15 as would be predicted by the incessant ovulation hypothesis, but this may
partly reflect the difficulty in recalling accurately age at menarche and of determining
precisely the age of onset of menopause. Also, starting or finishing menstruation
may not accurately reflect ovulation patterns.23 The suggested increased risk with
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use of fertility drugs, which stimulate the ovary to produce multiple ovulations, and
the protective effect of tubal ligation or hysterectomy also support the incessant
ovulation hypothesis. Parity, oral contraceptives and fertility drug use also fit the
high gonadotrophin hypothesis, but the associations with lactation, tubal ligation and
hysterectomy do not. The high gonadotrophin hypothesis would predict a reduced risk
for women taking hormone replacement therapy, but what little data there are do not
show a convincing association.23 It is possible that both hypotheses, and possibly
others, may be valid, with each explaining a proportion of all epithelial ovarian
cancers.
It must also be recognized that epithelial ovarian cancer is not a single pathological
entity, but may be divided on histology into serous, endometrioid, mucinous, clear
cell and other types. Each histological type may have a different aetiology although
this has not been properly examined in epidemiological studies. Similarly, epithelial
borderline malignant tumours (also called epithelial tumours of low malignant
potential), although sharing some of their histological characteristics with invasive
tumours, may differ in some of their aetiological risk factors.31
INFERTILITY, OVULATION INDUCTION AND OVARIAN CANCER
Case reports
In the 1980s case reports of ovarian cancer in women undergoing assisted conception
raised concerns about the use of ovarian stimulants in infertility treatment.32
Bamford and Steele33 documented the history of a 32-year-old woman with primary
infertility who had undergone eight cycles of ovulation induction with menopausal
gonadotrophins plus human chorionic gonadotrophin injections with a further three
cycles two years later. A 4-cm left-sided ovarian cyst was then found. Within one
month the ovary had increased to 25 cm diameter and surgery removed what was
found histologically to be an endometrioid tumour of the ovary, plus hyperplasia and
a well differentiated adenocarcinoma of the endometrium.
Land34 conducted a literature review to search for reports of ovarian neoplasms
arising in patients who had undergone ovulation induction. The first reported case in
the literature was that from Bamford and Steele33 described above. A further nine cases
had been published between 1982 and 1992 with ages at diagnosis ranging between
22 and 38 years. Seven of these nine cases were borderline or low malignant potential
tumours of serous histological type. Another review by Hull et al.35 reported 13 cases
published in the literature and added a further case of stage-3 poorly differentiated
serous carcinoma diagnosed eight months after Caesarean section – conception had
occurred after five cycles of gonadotrophin treatment. Unkila-Kallio et al.36 reported
on a case series of 11 women who developed malignant tumours of the ovary after
investigation or treatment of infertility. Two patients had granulosa cell tumours,
one a malignant teratoma and eight epithelial ovarian cancers (seven being invasive
serous papillary in type, and one mucinous). Of these eight women, four had used
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clomiphene for more than 12 cycles, but two had the diagnosis of carcinoma made
during investigations and before receiving any treatment.
A common feature of these case reports is the relatively short interval between use
of fertility drugs and the diagnosis of ovarian tumours (less than one to two years).
This would suggest that either fertility drugs stimulate the growth of pre-existing
lesions or more cases were diagnosed because of increased medical surveillance of
women who underwent investigation and treatment for infertility.
Epidemiological studies
Most early epidemiological studies used surrogate measures to investigate the
relationship between infertility and ovarian cancer with little information available
on physician-diagnosed infertility or its treatment. For example, ovarian cancer
occurrence was noted to be higher among childless women who tried to conceive
(presumably infertile) than among childless women who did not (most of whom were
presumably fertile), with the risk increasing with number of years of unprotected
intercourse (e.g. Booth et al.14).
One of the first studies to examine the relationship between infertility, its
treatment and ovarian cancer was a cohort study of 2632 Israeli women treated
for infertility between 1964 and 1974 and followed through the National Cancer
Registry to the end of 1981.37 The causes of infertility were defined as infertility
of the male partner, mechanical infertility (where there was evidence of ovulation
but mechanical factors were demonstrated at hysterosalpingography or laparoscopy),
hormonal infertility (with anovulation, amenorrhoea, oligomenorrhoea or irregular
periods) or infertility of unclassified origin. Analysis by type of infertility showed a
significantly increased risk of endometrial cancer and nonsignificantly elevated risks
of breast cancer and malignant melanoma for the hormonal group. Among women
with nonhormonal infertility, there was a suggestion of an increased risk of cancer of
the ovary but the number of cases was far too small to be conclusive. There was
no evidence of an association between ovulation-inducing drugs (i.e. clomiphene
citrate or human menopausal gonadotrophins) and cancer, but the paper does not
provide details on numbers of women to whom such drugs were prescribed. A recent
re-analysis of data from this cohort,38 with almost twice the length of follow-up
(mean = 21.4 years), showed an overall excess risk for endometrial cancer, but not for
ovarian cancer, and no relationship between site-specific cancer risks and treatment
with ovulation-inducing drugs.
Brinton et al.39 reviewed 2335 women evaluated for infertility at the Mayo Clinic
between 1935 and 1964, for cancer risks ; most cancers occurred at frequencies similar
to those observed in the general population. The risk of ovarian cancer was 60%
higher (although this was not statistically significant) in women who had progesterone
deficiency (an indication of anovulation or luteal phase defect) but not in those with
other causes of infertility. Some information on the effect of treatment was available
(primarily estrogen or progestogen concentrations), and it did not seem to affect the
risk of ovarian cancer.
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A pooled analysis of data from 12 US case–control studies conducted by the
Collaborative Ovarian Cancer Group and including 2197 cases of invasive epithelial
ovarian cancer showed no overall association between physician-diagnosed female
infertility and ovarian cancer.15,23 Three of the studies included in this pooled analysis
collected information on use of fertility drugs. Infertile women who had used fertility
treatment were at an increased risk of invasive epithelial ovarian cancer (relative risk
(RR) = 2.8 ; 95% CI = 1.3, 6.1), and of borderline ovarian tumours (RR = 4.0 ; 95% CI =
1.1, 13.9) compared to women without a history of infertility. The risk for the smaller
subgroup who never got pregnant was 27 times (95% CI = 2.3, 315.6) that of nulligravid
women who did not report infertility, whereas the risk for those who took drugs but
did achieve a pregnancy was not raised. The results generated a great deal of interest
because of the potentially serious implications for the rapidly expanding assisted
conception programmes throughout the world.40,41 Several possible explanations
could account for the association between failed infertility treatment and ovarian
cancer. As with all case–control studies, there is a possibility that recall bias might
have led to an overestimation of the magnitude of these associations.42 Even if the
observed association between infertility treatment and ovarian cancer risk were real,
women may have taken drugs for longer periods and in greater doses because they
had a certain type of infertility that predisposed them a priori to both infertility and
ovarian cancer.
This latter possibility was assessed by Rossing et al.43 in a cohort of 3837 women
from Seattle who had been evaluated for infertility between 1974 and 1985. The
authors found an increased risk of invasive or borderline ovarian tumours in infertile
women who took clomiphene relative to infertile women who had not taken this
drug (RR = 2.3 ; 95% CI = 0.5, 11.4). This risk was particularly high among women
who had taken clomiphene for more than 12 cycles (RR = 11.1 ; 95% CI = 1.5, 82.3).
Other small case–control studies have also reported on the relationship between
fertility treatment and ovarian cancer. Sushan et al.44 compared past use of fertility
drugs among 200 women with invasive or borderline epithelial ovarian cancer
identified through the Israel Cancer Registry with 408 healthy control women resident
in the same geographical areas. Twenty-four women with cancer (12%) and 29
healthy controls (7.1%) reported ever-use of fertility drugs, yielding a statistically
nonsignificant relative risk of 1.31 (95% CI = 0.63, 2.74). Twenty-two cancer cases
and 24 controls had used gonadotrophins alone or in combination with clomiphene
(RR = 1.42 ; 95% CI = 0.65, 3.2) and 11 cancer cases and 6 control women had
used gonadotrophins alone (RR = 3.19 ; 95% CI = 0.86, 11.82). The risk was parti-
cularly increased in the group of women with borderline tumours who had used
gonadotrophins (RR = 9.38 ; 95% CI = 1.66, 52.08).
A recent pooled analysis of data from eight population-based case–control studies
conducted between 1989 and 1999 in the US, Canada, Denmark and Australia, which
included over 5000 cases and 7000 controls, showed that among nulligravid women,
those who tried to become pregnant for more than five years had a 2.67-fold (95% CI =
1.91, 3.74) increase in the risk of developing ovarian cancer.45 Fertility drug use in
nulligravid women, but not in nulliparous women, was associated with an increased
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risk of borderline serous tumours (RR = 2.43 ; 95% CI = 1.01, 5.88), but not
with any invasive histologic subtype. These findings are rather consistent with
those reported by the large pooled analysis of US case–control studies described
above.15
The largest cohort study so far to have examined the association between ovarian
stimulation and risk of subsequent cancers consisted of 10,358 Australian women
who were referred for in vitro fertilization (IVF).46 Half of the cohort underwent
ovarian stimulation to induce multiple follicles (“exposed” group) whereas the
remaining women were untreated or had natural cycles without ovarian stimulation
(“unexposed” group). There was no evidence that ovarian stimulation was associated
with an increased risk of ovarian cancer but the follow-up of the cohort was
short (median length of follow-up for the exposed group was only five years).
This cohort was subsequently enlarged to include 20,656 IVF women who were
exposed to fertility drugs and 9044 who were not.47 The incidence of breast and
ovarian cancers was no higher than expected. The incidence of uterine cancer
was significantly higher than expected (RR = 2.47 ; 95% CI = 1.18, 5.18) in the
unexposed group but not in the exposed one. Women with unexplained infertility,
regardless of their exposure to ovarian stimulation, had a higher incidence of
uterine (RR = 4.59 ; 95% CI = 1.91, 11.0) and ovarian (RR = 2.64 ; 95% CI = 1.10,
6.35) cancers than expected. The main advantages of this study are its large
sample size and the availability of data on type of infertility and type of
treatment administered in the participating IVF centres. The main weaknesses are
the relatively low exposure levels (59% of the women in the exposed group had
less than three cycles of treatment, with only 11% having had six or more cycles),
the possibility of misclassification as information on exposure to fertility drugs
outside the participating centres was not available, the lack of data on potential
confounding factors such as gravidity and oral contraceptive use and the still
relatively short follow-up (median of seven years for women exposed to ovarian
stimulation).
Klip et al.48 reviewed papers published between 1966 and 1999 that included
information relevant to a link between sub-fertility, ovulation induction, and
cancers of the ovary, breast, endometrium, thyroid and malignant melanoma.
Many of the papers discussed above were included in this review. They concluded
that methodological defects might have accounted for most of the observed
inconsistencies. Lack of valid and standardized definitions of infertility and its types
and lack of information on lifetime exposure to fertility drugs may have played a
role. Potential for recall and selection bias was greater in case–control than in cohort
studies. In contrast, lack of control for confounding was a main limitation of cohort
studies as most of them relied on record linkage. Of the four cohort studies described
above,37−39,43,46,47 all were able to adjust for age at diagnosis, but only one43 was able
to take into account gravidity at enrolment, and none was able to adjust for oral
contraceptive use, family history or pelvic surgery, factors known to affect the risk
of ovarian cancer. In addition, many cohort studies were based on relatively small
sample sizes and short duration of follow-up.
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OUR FOLLOW-UP STUDY
With funding from Cancer Research UK, we have assembled a large cohort of 8799
women who were referred to the Royal Free and the University College Hospitals,
since the early 1960s, because of amenorrhoea or menstrual irregularity, infertility,
hirsuitism, thyroid or other endocrine disorders. This cohort is unique in that detailed
clinical notes were kept not only of the reasons for infertility, but also of any
diagnostic procedures performed on the patients, and of the type and doses of any
treatments prescribed, including number of cycles with fertility drugs and their
outcome (i.e. pregnancy and hyperstimulation). Clomiphene citrate was taken by
3419 (40%) patients in the cohort, with doses ranging from 250 mg to 1400 mg
per cycle, and for 1 to 55 cycles per patient (mean number of cycles per patient =
4, with 40% of these patients having had more than six cycles). Gonadotrophins
(usually human menopausal gonadotrophins plus human chorionic gonadotrophin)
were given to 886 (10%) patients in the cohort for 1 to 31 cycles (mean cycles per
patient = 5), with a total dose ranging from 4 to 1349 ampoules (mean 118) per
patient. Administration of a postal questionnaire via the patient’s current general
practitioner has allowed us to complement the information available in the clinical
notes with more up-dated information on the reproductive history of these women.
Patients have been flagged at the National Health Service Central Register (NHSCR) to
provide long-term follow-up, with ascertainment of incident cancer cases and deaths
(with information on cause of death) among cohort members. It is hoped that this
long-term follow-up study will help to clarify whether there is any true association
between infertility and/or its treatment, and the development of ovarian and other
cancers.
CONCLUSIONS
The evidence reviewed here seems to indicate that there is an association between
infertility and ovarian cancer risk, but it is uncertain whether this association is causal
or likely to be due to a common underlying mechanism. The association of ovarian
cancer risk with fertility treatment is more difficult to evaluate. Data from both cohort
and case–control studies seem to suggest that either there is no association, or if there
is one the magnitude of the treatment effect is relatively small. However, this does
not exclude the possibility that certain groups of patients may be at a particular high
risk. Further research is required to clarify these issues.
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